Table 3.

Laboratory abnormalities observed in the seven days following administration of dose 1 and dose 2

	Worst grade	After dose 1				After dose 2
		Vaccine group (N=30)		Placebo group (N=10)		Vaccine group (N=29)		Placebo group (N=10)
		n (%**)	95% CI	n (%**)	95% CI	n (%**)	95% CI	n (%**)	95% CI
Any laboratory abnormalities*		4 (13.3)	3.8–30.7	1 (10.0)	0.3–44.5	1 (3.4)	0.1–17.8	1 (10.0)	0.3–44.5
Blood chemistry
Blood bilirubin increased	mild	1 (3.3)	0.1–17.2	0 (0.0)	0.0–30.8	0 (0.0)	0.0–11.9	0 (0.0)	0.0–30.8
Haematological blood tests
Monocyte count increased	mild	2 (6.6)	0.8–22.1	0 (0.0)	0.0–30.8	0 (0.0)	0.0–11.9	0 (0.0)	0.0–30.8
Eosinophil count increased	mild	1 (3.3)	0.1–17.2	0 (0.0)	0.0–30.8	0 (0.0)	0.0–11.9	0 (0.0)	0.0–30.8
Lymphocyte count increased	mild	1 (3.3)	0.1–17.2	2 (20.0)	2.5–55.6	0 (0.0)	0.0–11.9	0 (0.0)	0.0–30.8
Neutrophil count decreased	mild	2 (6.6)	0.8–22.1	0 (0.0)	0.0–30.8	0 (0.0)	0.0–11.9	0 (0.0)	0.0–30.8
Erythrocyte sedimentation rate	mild	2 (6.6)	0.8–22.1	0 (0.0)	0.0–30.8	0 (0.0)	0.0–11.9	0 (0.0)	0.0–30.8
Urinalysis
Traces of protein	mild			0 (0.0)	0.0–30.8	1 (3.4)	0.1–17.8	1 (10.0)	0.3–44.5
Any serious adverse event		0		0		0		0

CI = confidence interval (%)

^*A subject with more than one finding in a specific category was counted only once.

^**Percentages based on total number of subjects in each treatment group.